• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Insiders Buying Fortress Biotech And 2 Other Stocks

    7/11/24 7:29:22 AM ET
    $AAN
    $FBIO
    $NXDT
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AAN alert in real time by email

    Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform.

    Fortress Biotech

    • The Trade: Fortress Biotech, Inc. (NASDAQ:FBIO) President, CEO and Chairman Lindsay A MD Rosenwald acquired a total of 5,000 shares at an average price of $7.35. To acquire these shares, it cost around $36,765.
    • What's Happening: On July 5, Fortress Biotech reported a pause in the payment of dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.
    • What Fortress Biotech Does: Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products.

    Aaron’s Company

    • The Trade: The Aaron’s Company, Inc. (NYSE:AAN) EVP, Gen Counsel/Corp Sec Rachel G George acquired a total of 500 shares at an average price of $8.48. To acquire these shares, it cost around $4,240.
    • What's Happening: On July 10, Jefferies analyst Kyle Joseph downgraded Aarons from Buy to Hold and lowered the price target from $11 to $10.1.
    • What Aaron’s Does: The Aarons Co Inc is a specialty retailer that has developed a lease-to-own model.

    NexPoint Diversified Real Estate Trust

    • The Trade: NexPoint Diversified Real Estate Trust (NYSE:NXDT) Matt McGraner bought a total of 15,000 shares at an average price of $5.37. To acquire these shares, it cost around $80,600.
    • What's Happening: On June 20, NexPoint Real Estate Opportunities, LLC announced its nomination of four highly qualified, independent candidates for election to the UDF IV Board of Trustees at its upcoming Annual Meeting of Shareholders.
    • What NexPoint Diversified Real Estate Trust Does: NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States.

    Read Next:

    • Wall Street’s Most Accurate Analysts Weigh In On 3 Consumer Stocks Delivering High-Dividend Yields
    Get the next $AAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAN
    $FBIO
    $NXDT

    CompanyDatePrice TargetRatingAnalyst
    Aarons Holdings Company Inc.
    $AAN
    6/7/2024Neutral
    BTIG Research
    Fortress Biotech Inc.
    $FBIO
    3/15/2024$10.00Buy
    ROTH MKM
    Aarons Holdings Company Inc.
    $AAN
    3/8/2024$7.00Market Perform
    TD Cowen
    Aarons Holdings Company Inc.
    $AAN
    1/2/2024Equal-Weight → Overweight
    Stephens
    Aarons Holdings Company Inc.
    $AAN
    7/10/2023$15.00 → $14.00Buy → Hold
    Loop Capital
    Aarons Holdings Company Inc.
    $AAN
    10/24/2022$6.50Neutral → Underperform
    BofA Securities
    Fortress Biotech Inc.
    $FBIO
    8/4/2022$6.00Buy
    Ladenburg Thalmann
    Aarons Holdings Company Inc.
    $AAN
    7/12/2022$16.00Hold
    Truist
    More analyst ratings

    $AAN
    $FBIO
    $NXDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 9:24:14 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 8:30:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

    ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 (clenbuterol), a well-characterized small-molecule β2-adrenergic agonist, in clinical development for the treatment of Pompe disease. Pompe d

    2/23/26 8:00:00 AM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $FBIO
    $NXDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Dondero James D was granted 212,863 shares (SEC Form 4)

    4 - NEXPOINT DIVERSIFIED REAL ESTATE TRUST (0001356115) (Issuer)

    1/21/26 6:00:18 PM ET
    $NXDT
    Real Estate Investment Trusts
    Real Estate

    Director Klein Dov was granted 27,322 shares, increasing direct ownership by 27% to 130,105 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    1/5/26 4:30:44 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Harvey Jimmie was granted 27,322 shares, increasing direct ownership by 23% to 146,704 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    1/5/26 4:30:43 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $FBIO
    $NXDT
    SEC Filings

    View All

    Fortress Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Fortress Biotech, Inc. (0001429260) (Filer)

    2/23/26 8:35:50 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NexPoint Diversified Real Estate Trust filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - NEXPOINT DIVERSIFIED REAL ESTATE TRUST (0001356115) (Filer)

    2/19/26 5:13:47 PM ET
    $NXDT
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SCHEDULE 13G/A filed by NexPoint Diversified Real Estate Trust

    SCHEDULE 13G/A - NEXPOINT DIVERSIFIED REAL ESTATE TRUST (0001356115) (Subject)

    1/30/26 2:18:19 PM ET
    $NXDT
    Real Estate Investment Trusts
    Real Estate

    $AAN
    $FBIO
    $NXDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Laffer Arthur B bought $42,043 worth of shares (15,052 units at $2.79), increasing direct ownership by 9% to 117,793 units (SEC Form 4)

    4 - NEXPOINT DIVERSIFIED REAL ESTATE TRUST (0001356115) (Issuer)

    12/8/25 4:19:09 PM ET
    $NXDT
    Real Estate Investment Trusts
    Real Estate

    Director Laffer Arthur B bought $13,976 worth of shares (5,101 units at $2.74), increasing direct ownership by 5% to 107,636 units (SEC Form 4)

    4 - NEXPOINT DIVERSIFIED REAL ESTATE TRUST (0001356115) (Issuer)

    12/3/25 9:41:28 PM ET
    $NXDT
    Real Estate Investment Trusts
    Real Estate

    Officer Richards Paul bought $13,900 worth of shares (5,000 units at $2.78), increasing direct ownership by 4% to 119,820 units (SEC Form 4)

    4 - NEXPOINT DIVERSIFIED REAL ESTATE TRUST (0001356115) (Issuer)

    11/20/25 6:27:17 PM ET
    $NXDT
    Real Estate Investment Trusts
    Real Estate

    $AAN
    $FBIO
    $NXDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on The Aaron's Company

    BTIG Research initiated coverage of The Aaron's Company with a rating of Neutral

    6/7/24 7:23:18 AM ET
    $AAN
    Diversified Commercial Services
    Consumer Discretionary

    ROTH MKM resumed coverage on Fortress Biotech with a new price target

    ROTH MKM resumed coverage of Fortress Biotech with a rating of Buy and set a new price target of $10.00

    3/15/24 7:18:10 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on The Aaron's Company with a new price target

    TD Cowen initiated coverage of The Aaron's Company with a rating of Market Perform and set a new price target of $7.00

    3/8/24 7:19:55 AM ET
    $AAN
    Diversified Commercial Services
    Consumer Discretionary

    $AAN
    $FBIO
    $NXDT
    Leadership Updates

    Live Leadership Updates

    View All

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

    SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

    4/1/25 4:01:16 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

    SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

    7/11/24 4:05:39 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $FBIO
    $NXDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortress Biotech Inc.

    SC 13G - Fortress Biotech, Inc. (0001429260) (Subject)

    10/25/24 10:15:19 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Fortress Biotech Inc.

    SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)

    9/25/24 4:45:18 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aarons Holdings Company Inc.

    SC 13G/A - Aaron's Company, Inc. (0001821393) (Subject)

    9/10/24 12:09:00 PM ET
    $AAN
    Diversified Commercial Services
    Consumer Discretionary

    $AAN
    $FBIO
    $NXDT
    Financials

    Live finance-specific insights

    View All

    UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 9:24:14 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 8:30:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NexPoint Diversified Real Estate Trust Announces 2025 Dividend Income Tax Treatment

    DALLAS, Jan. 30, 2026 /PRNewswire/ -- NexPoint Diversified Real Estate Trust ("NXDT") (NYSE:NXDT) announced today the final income allocations of the Company's 2025 dividend distributions on its common shares and preferred shares. The final income allocations as they will be reported on Form 1099-DIV are set forth in the following table: Common Shares (CUSIP # 65340G205) Ex Dividend Date Record Date Payable Date Distribution Per Share Taxable Ordinary Income Per Share1 Return of Capital Per Share 2/28/2025 2/28/2025 3/31/2025 $0.15000 $0.00000 $0.15000 5/9/2025 5/9/2025 6/30/

    1/30/26 9:00:00 AM ET
    $NXDT
    Real Estate Investment Trusts
    Real Estate